|
|
Post by mssciguy on Oct 15, 2015 17:01:45 GMT -5
Sanofi is best partner as they dont have competing meal time insulin..apidra doesnt have a major market while the others do... ( Novo and Lilly's - )... so these thoughts should be put to rest... Al owns 40% and knows whats best lol Yeah Al owns 40% and over 50% of shares are shorted. Not making any conclusions here, just saying, if Al wanted a squeeze, Al could get one. Likewise with Sanofi. We need to get Lizbeth Salander involved... |
|
|
|
Post by james on Oct 15, 2015 17:15:25 GMT -5
Yeah Al owns 40% and over 50% of shares are shorted. Not making any conclusions here, just saying, if Al wanted a squeeze, Al could get one. Likewise with Sanofi. We need to get Lizbeth Salander involved... How would Al do that since his shares are not the ones lent for shorting? Would he buy up a bunch of shares on the open market? Perhaps, but I really doubt that is in his plans or that he wants a higher ownership percentage. If I were Al and wanted additional shares, I would be working through convertible debt. |
|
|
|
Post by rvc on Oct 15, 2015 17:25:46 GMT -5
I dropped about 8 grand in MNKD so given that I guess I have a right to 'soft bash'. Like I said, it seems like the drug is great and I'll hop back in when it dips to a buck and a half. If it doesn't no problem, there are opportunities everywhere.
|
|
|
|
Post by mssciguy on Oct 15, 2015 18:00:22 GMT -5
I dropped about 8 grand in MNKD so given that I guess I have a right to 'soft bash'. Like I said, it seems like the drug is great and I'll hop back in when it dips to a buck and a half. If it doesn't no problem, there are opportunities everywhere. Yup you are right about opportunities. If interest rates go negative, look for precious metals to spike. I still have dry powder to average down if and when the time comes that (as @kastanes pointed out a while back) this drops to $2 or less. I will NOT do options because the stock price is manipulated, and it's not nice to see GS adjust to 2 cents away from target on a Friday, seriously, borderline organized crime in the options "industry" MNKD will be around for a long time. Humble origins with the most difficult kind of molecule possible for technosphere application. Clearly, pulmonary, vaccines and more are perfect and even easier Good luck man, and good luck Mannkind! |
|
|
|
Post by babaoriley on Oct 15, 2015 18:08:11 GMT -5
I wouldn't get my hopes up. SNY management has been increasingly silent in regards to Afrezza, and my best guess is they are simply 'playing out the string' until they can end the marketing arrangement in January. That being said, by all indications this is a great drug (although I doubt it will be nothing more than a niche drug) and after the relationship ends, it could be a great time to pick up shares of the stock for a fraction of its current price. I know this won't be well received but keep in mind, but the current SNY CEO was not in charge when this deal was made, and it sure appears to me that he's just not that into Afrezza. rvc, so that's your "best guess?" Could you list perhaps guesses 2 through 5, just out of curiosity. I'll even spot you one, "I know this won't be well received..." even though not phrased as a guess, I'm going to give you that, and that "guess" is certainly on the money. My best guess is that if I lost $8,000 on MNKD, I'd be having a friggen party tonight! |
|
|
|
Post by rrtzmd on Oct 15, 2015 19:01:55 GMT -5
Sanofi is best partner as they dont have competing meal time insulin..apidra doesnt have a major market while the others do... ( Novo and Lilly's - )... so these thoughts should be put to rest... Al owns 40% and knows whats best lol Yeah Al owns 40% and over 50% of shares are shorted. Not making any conclusions here, just saying, if Al wanted a squeeze, Al could get one. Likewise with Sanofi. We need to get Lizbeth Salander involved... Since Al does have such a large interest, would it be possible that he may have "shorted against the box" to reduce the risk of serious loss? |
|
|
|
Post by dreamboatcruise on Oct 15, 2015 19:10:34 GMT -5
I wouldn't get my hopes up. SNY management has been increasingly silent in regards to Afrezza, and my best guess is they are simply 'playing out the string' until they can end the marketing arrangement in January. That being said, by all indications this is a great drug (although I doubt it will be nothing more than a niche drug) and after the relationship ends, it could be a great time to pick up shares of the stock for a fraction of its current price. I know this won't be well received but keep in mind, but the current SNY CEO was not in charge when this deal was made, and it sure appears to me that he's just not that into Afrezza. What other biotec company would ever partner with Sanofi after getting a reputation for sandbagging like that? |
|
|
|
Post by tmann on Oct 15, 2015 19:42:25 GMT -5
I talked with Sanofi's head of R&D at the SENS Rejuvenation Biotech conference in SF a few weeks ago. When I asked him about Afrezza he said, "It's a fantastic drug." That for a scientist, is enormous enthusiasm.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 15, 2015 20:42:08 GMT -5
I dropped about 8 grand in MNKD so given that I guess I have a right to 'soft bash'. Like I said, it seems like the drug is great and I'll hop back in when it dips to a buck and a half. If it doesn't no problem, there are opportunities everywhere. Please go back to YMB! We're all down brother. I am down, you're down, he's down, everyone. But this message board is for sharing ideas, not bashing! |
|
|
|
Post by trenddiver on Oct 15, 2015 21:20:23 GMT -5
Yeah Al owns 40% and over 50% of shares are shorted. Not making any conclusions here, just saying, if Al wanted a squeeze, Al could get one. Likewise with Sanofi. We need to get Lizbeth Salander involved... Since Al does have such a large interest, would it be possible that he may have "shorted against the box" to reduce the risk of serious loss? This thought has been well discussed in the past. The short answer is NO. However he may have lent his shares and grabbed the high rate interest. trend |
|
|
|
Post by kball on Oct 15, 2015 21:41:38 GMT -5
Since Al does have such a large interest, would it be possible that he may have "shorted against the box" to reduce the risk of serious loss? This thought has been well discussed in the past. The short answer is NO. However he may have lent his shares and grabbed the high rate interest.trend Wait...So Matt was speaking indirectly to Al then? I can't see that. |
|
|
|
Post by suebeeee1 on Oct 17, 2015 15:44:05 GMT -5
Since Al does have such a large interest, would it be possible that he may have "shorted against the box" to reduce the risk of serious loss? This thought has been well discussed in the past. The short answer is NO. However he may have lent his shares and grabbed the high rate interest. trend Yeah, then he had a responsibility to all shareholders to call them back. While the stock goes down, he makes the shorts possible by loaning his own shares our to these blood suckers? Please don't feed the sharks! |
|
|
|
Post by mnkdlonginbrla on Oct 18, 2015 8:32:40 GMT -5
FYI
SANOFI IR - The Investor Relations Mobile Application
This is a great user friendly App for Sanofi Investors.
|
|
|
|
Post by mnholdem on Oct 18, 2015 9:13:35 GMT -5
Didn't Matt make it clear at a recent conference call that no company employee is permitted to short MNKD stock or have shares in any account that allows the shares to be loaned? I simply don't believe that Matt would be that disengenuous to make such a statement if the Chairman of the Board were doing otherwise.
Sorry, but I don't buy into the popular bash against Al or MNKD management. Silence does not imply complicity, IMHO.
|
|
|
|
Post by mnkdlonginbrla on Oct 18, 2015 9:46:59 GMT -5
Listened to webcast on new SANOFI IR App
Sanofi
06/09/2015
IR Thematic Conference Call on Diabetes
Afrezza update by Andrew Purcell 23.41 minutes
|
|
